Recombinant antibodies possessing novel effector functions.
The introduction into lymphocytes of immunoglobulin-gene DNA that has been manipulated in vitro allows the production of novel antibodies. In this way, cell lines have been established that secrete hapten-specific antibodies in which the Fc portion has been replaced either with an active enzyme moiety or with polypeptide displaying c-myc antigenic determinants.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics*; D000936:Antigen-Antibody Complex; D002460:Cell Line; D002678:Chimera; D003001:Cloning, Molecular; D004262:DNA Restriction Enzymes; D004220:Disulfides; D005796:Genes; D006241:Haptens; D006825:Hybridomas / Q000276:immunology; D007140:Immunoglobulin Fab Fragments / Q000235:genetics; D008214:Lymphocytes / Q000276:immunology; D051379:Mice; D008836:Micrococcal Nuclease / Q000378:metabolism; D009857:Oncogenes; D010954:Plasmacytoma / Q000276:immunology; D010957:Plasmids; D013211:Staphylococcus aureus / Q000201:enzymology; D014162:Transfection
D000911:Antibodies, Monoclonal; D000936:Antigen-Antibody Complex; D004220:Disulfides; D006241:Haptens; D007140:Immunoglobulin Fab Fragments; D004262:DNA Restriction Enzymes; D008836:Micrococcal Nuclease